NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ...

In 2024, the FDA granted 510(k) clearance to a hemodialysis machine capable of delivering online high-volume hemodiafiltration. Since then, companies have started phased introduction of the system ...

A small but mighty piece of lab equipment, about the size of a cellphone, has arrived at the International Space Station ...

According to a Reuters report on February 18, Australia’s CSL said it had granted Eli Lilly and Company (NYSE:LLY) certain ...

Women are more likely to experience chronic pain, studies have found, and their pain lasts longer, on average. New research ...

Researchers hope the findings could lead to non‑opioid pain relief and help ensure that women’s pain is taken seriously.

A small but mighty piece of lab equipment, about the size of a cellphone, has arrived at the International Space Station ...

• Overall, we did not find sufficient evidence to show that medicines that block interleukin-1 (a protein involved in immune responses) are effective treatments for people with COVID-19, or whether ...

Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...